10/550.039

Page 2 of 10

RECEIVED CENTRAL FAX CENTER AUG 1 5 2006

In the Claims

The following listing of claims will replace all prior versions and listings of claims in the application:

Claims

(Currently Amended) A compound of the formula (I), or a pharmaceutically-1. acceptable salt, or an in-vivo-hydrolysable ester thereof,

wherein -N-HET is:

wherein

The same of the sa

R¹ is (1-4C)alkyl;

or R1 is selected from a substituent from the group

(R¹a) wherein R¹ is halogen, hydroxy, (1-4C)alkoxy, (2-4C)alkenyloxy, (2-4C)alkenyl, (2-4C)alkynyl (optionally substituted on the terminal carbon by CH2=CH-, di(1-4C)alkylamino, AR2, AR2a or AR2b, wherein AR2, AR2a and AR2b are defined hereinbelow), (3-6C)cycloalkyl, (3-6C)cycloalkenyl, amino, (1-4C)alkylamino, di-(1-4C)alkylamino, (2-4C)alkenylamino, (1-4C)alkyl-3(O)q- (wherein q is 0, 1 or 2), (1-4C)alkylcarbonylamino, ; or R1 is selected from the group

(R1b) wherein R1 is a (1-4C)alkyl group which is substituted by one substituent selected from hydroxy, halo, (1-4C)alkoxy, amino, (1-4C)alkylamino, di(1-4C)alkylamino, cyano, azido, (2-4C)alkenyloxy, (1-4C)alkyl-S(O)q- (wherein q is 0, 1 or 2), AR1-S(O)q- (wherein q is 0, 1 or 2 and AR1 is defined hereinbelow), AR2-S(O)q- (wherein q is 0, 1 or 2), AR2a-S(O)q-(wherein q is 0, 1 or 2), benzyl-S(O)q- (wherein q is 0, 1 or 2), (3-6C)cycloalkyl, (3-6C)cycloalkenyl, (1-4C)alkyl-C)CO-NH-, (1-4C)alkyl-NHCO-O-, (1-4C)alkylaminocarbonyl, di(1-4C)alkylaminocarbonyl, Fl2NC(=NH)S-;

10/550,039

Page 3 of 10

or R1 is selected from a group of formula (R1c1):-

(R1c1) a fully saturated 4-membered monocyclic ring containing 1 or 2 heteroatoms independently selected from C, N and S (optionally oxidised), and linked via a ring nitrogen or carbon atom; or

or R1 is selected from the group

(R¹d) cyano, nitro, azido, formyl, (1-4C)alkylcarbonyl, (1-4C)alkoxycarbonyl, H₂NC(O)-, (1-4C)alkyINHC(O)-;

and wherein at each occurrence of an R1 substituent containing an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl moiety in (R1a), (R1b) or (R1c1) each such moiety is optionally further substituted on an available carbon atom with one, two, three or more substituents independently selected from F, CI Br, OH and CN;

Q is:

wherein R2 and R3 are independently selected from H, F, CI, CF3, OMe, SMe, Me and Et; wherein T is selected from the groups in (TAa1) to (TAa12):

Application No.: Amendment Dated:

10/550,039 August 15, 2006

Page 4 of 10

wherein:

R^{6h} is selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, (1-4C)alkanoyl, carbamoyl and cyano;

R^{4h} and R^{5h} are independently selected from hydrogen, halo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (1-4C)alkylS(O)q- (q is 0, 1 or 2), (1-4C)alkanoyl, (1-4C)alkoxycarbonyl, benzyloxy-(1-4C)alkyl, (2-4C)alkanoylamino, -CONRcRv and -NRcRv wherein any (1-4C)alkyl group contained in the preceding values for R^{4h} and R^{5h} is optionally substituted by

up to three substituents independently selected from hydroxy (not on C1 of an alkoxy group, and excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)q- (q is 0, 1 or 2), (1-4C)alkylSO2-NRv-, (1-4C)alkoxycarbonyl, -CONRcRv, and -NRcRv (not on C1 of an alkoxy group, and excluding geminal disubstitution); wherein Rv is hydrogen or (1-4C)alkyl and Rc is as hereinafter defined;

10/550,039

Page 5 of 10

R^{4h} and R^{5h} may further be independently selected from (1-4C)alkyl (optionally substituted by one, two or three substituents independently selected from hydroxy (excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, phosphoryl [-O-P(O)(OH)2, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)2 and mono- and di-(1-4C)alkox/ derivatives thereof], hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)q- (q is 0, 1 or 2), (1-4C)alkylSO2-NRv-, (1-4C)alkoxycarbonyl, -CONRcRv, -NRcRv (excluding geminal disubstitution), ORc, and phenyl (optionally substituted by one, two or three substituents independently selected from (1-4C)alkyl, (1-4C)alkoxy and halo)}; wherein Rv is hydrogen or (1-사C)alkyl and Rc is as hereinafter defined; and wherein any (1-4C)alkyl group contained in the immediately preceding optional substituents (when R4h and R5h are independently (1-4C)alkyl) is itself optionally substituted by up to three substituents independently selected from hydroxy (not on C1 of an alkoxy group, and excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)q- (q is 0, 1 or 2), (1-4C)alkyISO2-NRv-, (1-4C)alkoxycarbonyl, -CONRcRv, and -NRcRv (not on C1 of an alkoxy group, and excluding geminal disubstitution); wherein Rv is hydrogen or (1-4C)alkyl and Rc is as hereinafter defined;

or R4h is selected from one of the groups in (TAaa) to (TAab) below, or (where appropriate) one of R^{4h} and Rth is selected from the above list of R^{4h} and R^{5h} values, and the other is selected from one of the groups in (TAaa) to (TAab) below :-

(TAaa) a group of the formula (TAaa1)

wherein Zo is hydrogen or (1-4C)alkyl;

Xº and Yº are independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, halo, cyano, nitro, (1-4C)alkyl/3(O)g- (q is 0, 1 or 2), RvRwNSO₂-, trifluoromethyl, pentafluoroethyl, (1-4C)alkanoyl and -CONRvRw [wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl];

(TAab) an acetylene of the fcrmula -=-H or -=-(1-4C)alkyl; wherein Rc is selected from groups (Rc1) to (Rc2) :-

(Rc1) (1-6C)alkyl (optionally substituted by one or more (1-4C)alkanoyl groups (including geminal disubstitution) and/or optionally monosubstituted by cyano, (1-4C)alkoxy, trifluoromethyl, (1-4C)alkoxycarbonyl, phenyl (optionally substituted as for AR1 defined

10/550,039

Page 6 of 10

hereinafter), (1-4C)alkylS(O)q- (q is 0, 1 or 2); or, on any but the first carbon atom of the (1-6C)alkyl chain, optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy and fluoro, and/or optionally monosubstituted by oxo, -NRvRw [wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl], (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkyl $\S(O)_pNH$ - or (1-4C)alkyl $\S(O)_p$ -((1-4C)alkyl $\S(O)_p$ -((1-4C)alkyl) $\S(O)_p$ -(1-4C)alkyl (Rc2) R13CO-, R13SO2- or R15CS-

wherein R13 is selected from (Fc2a) to (Rc2d):-

hydrogen, (1-4C)alkoxycarbonyl, trifluoromethyl and -NRvRw [wherein Rv is (Rc2a) hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl];

(Rc2b) (1-10C)alkyl

(optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkanoyl, carboxy, phosphoryl [-O-P(O)(OH)₂, and mono- and di-(1-4C)alkox)¹ derivatives thereof], phosphiryl [-O-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from phosphonate [phosphono, -P(O)(OH)₂, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinate [-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, trifluoroniethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)all:anoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)pNH-, (1-4C)alkylS(O)p-((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)pNH-, fluoro(1-4C)alkylS(O)p 4C)alkylS(O) $_p$ ((1-4C)alkyl)N-, (1-4C)alkylS(O) $_q$ - [the (1-4C)alkyl group of (1-4C)alkylS(O) $_q$ being optionally substituted by one substituent selected from hydroxy, (1-4C)alkoxy, (1-4C)alkanoyl, phosphoryl [-O-P(O)(OH)₂, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)2 and mono- and di-(1-4C)alkoxy derivatives thereof], amino, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, carboxy, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alky aminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)pNH-, (1-4C)alkylS(O)p-((1-4C)alkyl)N-, and (1-4C)alkylS(O)q-; R¹⁴C(O)O(1-6C)alkyl wherein R¹⁴ is AR1, AR2, (1-4C)alkylamino (the (1-(Rc2c) 4C)alkyl group being optionally substituted by (1-4C)alkoxycarbonyl or by carboxy), benzyloxy-(1-4C)alkyl or (1-1(iC)alkyl {optionally substituted as defined for (Rc2b)}; R¹⁵O- wherein R¹⁵ is benzyl, (1-6C)alkyl (optionally substituted as defined for (Rc2d)

,·. : '

Application No.:

10/550,039 Amendment Dated: August 15, 2006

Page 7 of 10

(Rc2c)) or AR2b;

wherein

AR1 is an optionally substituted phenyl or optionally substituted naphthyl;

AR2 is an optionally substituted 5- or 6-membered, fully unsaturated monocyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-3 bonds), and linked via a ring carbon atom, or a ring nitrogen atom if the ring is not thereby cuaternised;

AR2a is a partially hydrogenated version of AR2, linked via a ring carbon atom or linked via a ring nitrogen atom if the ring is not thereby quaternised;

AR2b is a fully hydrogenated version of AR2, linked via a ring carbon atom or linked via a ring nitrogen atom.

- 2. (Canceled)
- 3. (Canceled)
- (Previously Presented) The compound of claim 1, wherein ${}^{\hat{}}R^2$ and R^3 are 4. independently hydrogen or fluoro.
- (Previously Presented) The compound of claim 1, wherein T is selected from TAa1, 5. TAa5, TAa7 and TAa8.
- (Currently Amended) The compound of claim 1, wherein R1 is selected from R1 to 6. Rtd Rta, Rtb, Rtc, and Rtd.
- (Currently Amended) The compound of claim 1, which is a compound of the formula 7. (1B)

10/550,039

Page 8 of 10

$$R^2$$
 $N=N$
 $N=N$
 R^1

<u>wherein</u>

R1 is (1-4C)alkyl;

R2 and R3 are independently hydrogen or fluoro; and T is selected from TAa1, TAa5 TAa7 and TAa8.

- 8. (Canceled)
- (Previously Presented) A method for producing an antibacterial effect in a warm 9 blooded animal which comprises administering to said animal an effective amount of a compound of claim 1.
- 10. (Canceled) ---
- 11. (Canceled)
- (Previously Presented) A pharmaceutical composition which comprises a compound 12. of claim 1, and a pharmaceutically-acceptable diluent or carrier.
- 13. (Canceled)
- (Previously Presented) A compound which is: 14.
- (5R)-3-[3-Fluoro-4-(3-niethylisoxazol-5-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1yl)methyl]-1,3-oxazolidin-2-one;
- (5R)-3-(4-Isoxazol-3-ylphenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3oxazolidin-2-one; or
- (5R)-3-[4-(1-Benzyl-1H-1,2,3-triazol-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3triazol-1-yl)methyl]-1,3-oxazolidin-2-one.